{"id":910,"date":"2026-03-12T17:26:37","date_gmt":"2026-03-12T16:26:37","guid":{"rendered":"https:\/\/biotechlerncenter.iph-multisite.berta-bewegt.ch\/?page_id=910"},"modified":"2026-03-13T18:28:07","modified_gmt":"2026-03-13T17:28:07","slug":"3-attaques-specifiques","status":"publish","type":"page","link":"https:\/\/biotechlerncenter.interpharma.ch\/fr\/sujets\/medicaments-anti-cancereux\/3-attaques-specifiques\/","title":{"rendered":"3. Attaques sp\u00e9cifiques"},"content":{"rendered":"\n

La nouvelle g\u00e9n\u00e9ration, en fait il s’agit de la deuxi\u00e8me g\u00e9n\u00e9ration de m\u00e9dicaments contre le cancer dont quelques-uns sont d\u00e9j\u00e0 sur le march\u00e9 et d’autres sont en train d’\u00eatre exp\u00e9riment\u00e9s cliniquement, attaque donc de fa\u00e7on sp\u00e9cifique les cellules tumorales et laisse en paix les cellules saines en train de se diviser. Ces m\u00e9dicaments furent d\u00e9velopp\u00e9s dans le but de r\u00e9soudre les probl\u00e8mes mol\u00e9culaires ayant conduit \u00e0 la formation de la tumeur.<\/p>\n\n\n\n

Le Glivec et l’Herceptin sont deux exemples de cette nouvelle g\u00e9n\u00e9ration de m\u00e9dicaments (le chapitre Anticorps monoclonaux<\/a> donne des informations au sujet de l’Herceptin). Le Glivec est efficace contre une forme de cancer du syst\u00e8me sanguin, la leuc\u00e9mie my\u00e9lo\u00efde chronique (LMC). Aux Etats-Unis ainsi qu’en Europe, quelques 5’000 nouveaux cas de LMC sont enregistr\u00e9s par ann\u00e9e, cette forme de cancer compte ainsi parmi les moins fr\u00e9quentes. La LMC passe d’une phase chronique de plusieurs ann\u00e9es \u00e0 un stade avanc\u00e9 qui finalement va d\u00e9g\u00e9n\u00e9rer en une prolif\u00e9ration explosive de globules blancs (leucocytes) et conduire au d\u00e9c\u00e8s de la personne concern\u00e9e.<\/p>\n\n\n\n

Avant l’arriv\u00e9e du Glivec, les m\u00e9decins traitaient les patients atteints de LMC la plupart du temps par des greffes de moelle osseuse. Toutefois, le nombre insuffisant de donneurs de moelle osseuse devenait probl\u00e9matique. Les patients devaient attendre durant de longs mois. En outre, seul un cinqui\u00e8me des patients se pr\u00eate \u00e0 ce traitement. Le traitement par un autre m\u00e9dicament, l’interf\u00e9ron, aida \u00e0 prolonger la vie, mais celui-ci ne fut pas bien support\u00e9 par la plupart des patients.<\/p>\n","protected":false},"excerpt":{"rendered":"

La nouvelle g\u00e9n\u00e9ration, en fait il s’agit de la deuxi\u00e8me g\u00e9n\u00e9ration de m\u00e9dicaments contre le cancer dont quelques-uns sont d\u00e9j\u00e0 sur le march\u00e9 et d’autres sont en train d’\u00eatre exp\u00e9riment\u00e9s cliniquement, attaque donc de fa\u00e7on sp\u00e9cifique les cellules tumorales et laisse en paix les cellules saines en train de se diviser. Ces m\u00e9dicaments furent d\u00e9velopp\u00e9s […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":946,"menu_order":2,"comment_status":"closed","ping_status":"closed","template":"page-templates\/unterthema.php","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"class_list":["post-910","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"\n3. Attaques sp\u00e9cifiques - biotechlerncenter<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/biotechlerncenter.interpharma.ch\/themen\/krebs-neue-medikamente\/3-spezifische-attacke\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"3. Attaques sp\u00e9cifiques\" \/>\n<meta property=\"og:description\" content=\"La nouvelle g\u00e9n\u00e9ration, en fait il s’agit de la deuxi\u00e8me g\u00e9n\u00e9ration de m\u00e9dicaments contre le cancer dont quelques-uns sont d\u00e9j\u00e0 sur le march\u00e9 et d’autres sont en train d’\u00eatre exp\u00e9riment\u00e9s cliniquement, attaque donc de fa\u00e7on sp\u00e9cifique les cellules tumorales et laisse en paix les cellules saines en train de se diviser. Ces m\u00e9dicaments furent d\u00e9velopp\u00e9s […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/biotechlerncenter.interpharma.ch\/themen\/krebs-neue-medikamente\/3-spezifische-attacke\/\" \/>\n<meta property=\"og:site_name\" content=\"biotechlerncenter\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-13T17:28:07+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/biotechlerncenter.interpharma.ch\/themen\/krebs-neue-medikamente\/3-spezifische-attacke\/\",\"url\":\"https:\/\/biotechlerncenter.interpharma.ch\/themen\/krebs-neue-medikamente\/3-spezifische-attacke\/\",\"name\":\"3. Attaques sp\u00e9cifiques - biotechlerncenter\",\"isPartOf\":{\"@id\":\"https:\/\/biotechlerncenter.interpharma.ch\/#website\"},\"datePublished\":\"2026-03-12T16:26:37+00:00\",\"dateModified\":\"2026-03-13T17:28:07+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/biotechlerncenter.interpharma.ch\/themen\/krebs-neue-medikamente\/3-spezifische-attacke\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/biotechlerncenter.interpharma.ch\/themen\/krebs-neue-medikamente\/3-spezifische-attacke\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/biotechlerncenter.interpharma.ch\/themen\/krebs-neue-medikamente\/3-spezifische-attacke\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Start\",\"item\":\"https:\/\/biotechlerncenter.interpharma.ch\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sujets\",\"item\":\"https:\/\/biotechlerncenter.interpharma.ch\/fr\/sujets\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"M\u00e9dicaments anti-canc\u00e9reux\",\"item\":\"https:\/\/biotechlerncenter.interpharma.ch\/fr\/sujets\/medicaments-anti-cancereux\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"3. Attaques sp\u00e9cifiques\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/biotechlerncenter.interpharma.ch\/#website\",\"url\":\"https:\/\/biotechlerncenter.interpharma.ch\/\",\"name\":\"biotechlerncenter\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/biotechlerncenter.interpharma.ch\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"3. Attaques sp\u00e9cifiques - biotechlerncenter","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/biotechlerncenter.interpharma.ch\/themen\/krebs-neue-medikamente\/3-spezifische-attacke\/","og_locale":"fr_FR","og_type":"article","og_title":"3. Attaques sp\u00e9cifiques","og_description":"La nouvelle g\u00e9n\u00e9ration, en fait il s’agit de la deuxi\u00e8me g\u00e9n\u00e9ration de m\u00e9dicaments contre le cancer dont quelques-uns sont d\u00e9j\u00e0 sur le march\u00e9 et d’autres sont en train d’\u00eatre exp\u00e9riment\u00e9s cliniquement, attaque donc de fa\u00e7on sp\u00e9cifique les cellules tumorales et laisse en paix les cellules saines en train de se diviser. Ces m\u00e9dicaments furent d\u00e9velopp\u00e9s […]","og_url":"https:\/\/biotechlerncenter.interpharma.ch\/themen\/krebs-neue-medikamente\/3-spezifische-attacke\/","og_site_name":"biotechlerncenter","article_modified_time":"2026-03-13T17:28:07+00:00","twitter_card":"summary_large_image","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/biotechlerncenter.interpharma.ch\/themen\/krebs-neue-medikamente\/3-spezifische-attacke\/","url":"https:\/\/biotechlerncenter.interpharma.ch\/themen\/krebs-neue-medikamente\/3-spezifische-attacke\/","name":"3. Attaques sp\u00e9cifiques - biotechlerncenter","isPartOf":{"@id":"https:\/\/biotechlerncenter.interpharma.ch\/#website"},"datePublished":"2026-03-12T16:26:37+00:00","dateModified":"2026-03-13T17:28:07+00:00","breadcrumb":{"@id":"https:\/\/biotechlerncenter.interpharma.ch\/themen\/krebs-neue-medikamente\/3-spezifische-attacke\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/biotechlerncenter.interpharma.ch\/themen\/krebs-neue-medikamente\/3-spezifische-attacke\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/biotechlerncenter.interpharma.ch\/themen\/krebs-neue-medikamente\/3-spezifische-attacke\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Start","item":"https:\/\/biotechlerncenter.interpharma.ch\/fr\/"},{"@type":"ListItem","position":2,"name":"Sujets","item":"https:\/\/biotechlerncenter.interpharma.ch\/fr\/sujets\/"},{"@type":"ListItem","position":3,"name":"M\u00e9dicaments anti-canc\u00e9reux","item":"https:\/\/biotechlerncenter.interpharma.ch\/fr\/sujets\/medicaments-anti-cancereux\/"},{"@type":"ListItem","position":4,"name":"3. Attaques sp\u00e9cifiques"}]},{"@type":"WebSite","@id":"https:\/\/biotechlerncenter.interpharma.ch\/#website","url":"https:\/\/biotechlerncenter.interpharma.ch\/","name":"biotechlerncenter","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/biotechlerncenter.interpharma.ch\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"}]}},"_links":{"self":[{"href":"https:\/\/biotechlerncenter.interpharma.ch\/fr\/wp-json\/wp\/v2\/pages\/910","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/biotechlerncenter.interpharma.ch\/fr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/biotechlerncenter.interpharma.ch\/fr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/biotechlerncenter.interpharma.ch\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/biotechlerncenter.interpharma.ch\/fr\/wp-json\/wp\/v2\/comments?post=910"}],"version-history":[{"count":2,"href":"https:\/\/biotechlerncenter.interpharma.ch\/fr\/wp-json\/wp\/v2\/pages\/910\/revisions"}],"predecessor-version":[{"id":3226,"href":"https:\/\/biotechlerncenter.interpharma.ch\/fr\/wp-json\/wp\/v2\/pages\/910\/revisions\/3226"}],"up":[{"embeddable":true,"href":"https:\/\/biotechlerncenter.interpharma.ch\/fr\/wp-json\/wp\/v2\/pages\/946"}],"wp:attachment":[{"href":"https:\/\/biotechlerncenter.interpharma.ch\/fr\/wp-json\/wp\/v2\/media?parent=910"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}